Literature DB >> 2006997

Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril.

J E Jalil1, J S Janicki, R Pick, K T Weber.   

Abstract

Progressive myocardial fibrosis, including the accumulation of collagen within the adventitia of intramyocardial coronary arteries, is seen in the hypertrophied rat myocardium secondary to renovascular hypertension (RHT) and has been held responsible for alterations in myocardial diastolic stiffness. This study was undertaken to test the hypothesis that this presumptive angiotensin-aldosterone mediated fibrosis and its functional consequences could be favorably altered by an antihypertensive oral dose (50 mg/kg/day) of the angiotensin converting enzyme (ACE) inhibitor captopril. Three groups were studied: control; untreated RHT for 8 weeks; treated RHT, with captopril started 48 h before banding and continued for 8 weeks. Interstitial collagen volume fraction and perivascular collagen area (morphometry), the fibrillar nature of collagen (picrosirius polarization), and the end diastolic stress-strain relation of the intact left ventricle were examined in each group. In comparison to untreated animals with RHT, we found that captopril, begun prior to banding, attenuated interstitial and perivascular fibrosis and prevented hypertrophy and the rise in diastolic stiffness 8 weeks later. Thus, an adverse accumulation of collagen in the interstitium and around intramyocardial coronary arteries, and its functional consequences in the rat with RHT, can be prevented by captopril. Other ACE inhibitors may have similar salutary effects, but remain to be evaluated. The pathogenetic origin of myocardial fibrosis in RHT requires further investigation, but appears to be related to the angiotensin-aldosterone system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006997     DOI: 10.1093/ajh/4.1.51

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  16 in total

1.  Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology.

Authors:  Yanfei Qi; Juan Zhang; Colleen T Cole-Jeffrey; Vinayak Shenoy; Andrew Espejo; Mina Hanna; Chunjuan Song; Carl J Pepine; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

Review 2.  Vascular remodeling and mineralocorticoids.

Authors:  K T Weber; Y Sun; S E Campbell; S H Slight; V K Ganjam
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

3.  Angiotensin II stimulates hyperplasia but not hypertrophy in immature ovine cardiomyocytes.

Authors:  N C Sundgren; G D Giraud; P J S Stork; J G Maylie; K L Thornburg
Journal:  J Physiol       Date:  2003-03-07       Impact factor: 5.182

Review 4.  Role of ACE inhibitors in hypertension with left ventricular hypertrophy.

Authors:  A M Richards; M G Nicholls; I G Crozier
Journal:  Br Heart J       Date:  1994-09

5.  An updated concept for left ventricular hypertrophy risk in hypertension.

Authors:  Edward D Frohlich
Journal:  Ochsner J       Date:  2009

6.  Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice.

Authors:  T Matsusaka; H Katori; T Inagami; A Fogo; I Ichikawa
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

7.  Semiquantitative analysis of collagen types in the hypertrophied left ventricle.

Authors:  K A Linehan; A M Seymour; P E Williams
Journal:  J Anat       Date:  2001-01       Impact factor: 2.610

8.  Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.

Authors:  N E Rhaleb; H Peng; X P Yang; Y H Liu; D Mehta; E Ezan; O A Carretero
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

9.  Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture.

Authors:  H Matsubara; M Kanasaki; S Murasawa; Y Tsukaguchi; Y Nio; M Inada
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 10.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.